basosquamous carcinoma
basosquamous carcinoma
Explore linked clinical trials. Standard reference: MONDO:00032641 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Hemic and Lymphatic Diseases, Infections, Lynch syndrome 2, Muir-Torre syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Sezary syndrome, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, adenocarcinoma, anaplastic large cell lymphoma, apocrine adenocarcinoma, basal cell carcinoma, basal cell neoplasm, basosquamous carcinoma, carcinoma, cutaneous neuroendocrine carcinoma, cystic, mucinous, and serous neoplasm, eccrine porocarcinoma, epithelial neoplasm, extramammary Paget disease, hereditary disease, hereditary neoplastic syndrome, hereditary skin disorder, hidradenocarcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant syringoma, mycosis fungoides, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, polyomavirus infectious disease, primary cutaneous T-cell non-Hodgkin lymphoma, primitive neuroectodermal tumor, sebaceous gland disorder, sebaceous gland neoplasm, signet ring cell carcinoma, skin basal cell carcinoma, skin disorder, skin neoplasm, skin squamous cell carcinoma, sweat gland cancer, sweat gland carcinoma, viral infectious disease, vulvar squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-13 | NCT02978625 |